Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$8.04 +6.6%	$8.63	$6.51 ▼ $13.27	$7.99M	1.63	1,538 shs	2,487 shs
CHRO Chromocell Therapeutics	$1.34 +6.3%	$6.68	$4.50 ▼ $38.00	$8.69M	3.63	47,337 shs	194,032 shs
CLRB Cellectar Biosciences	$4.42	$6.66	$4.31 ▼ $68.70	$8M	0.42	113,200 shs	738,736 shs
WINT Windtree Therapeutics	$0.52 -3.6%	$0.69	$0.36 ▼ $662.00	$1.96M	0.63	11.35 million shs	1.11 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	+1.71%	+1.40%	-11.01%	0.00%	+3.01%
CHRO Chromocell Therapeutics	0.00%	0.00%	0.00%	-86.60%	-83.00%
CLRB Cellectar Biosciences	0.00%	-6.16%	-7.53%	-39.86%	-92.63%
WINT Windtree Therapeutics	-3.58%	-11.99%	-37.65%	-37.61%	-99.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	2.7389 of 5 stars	3.5	3.0	0.0	0.0	3.3	0.8	0.6
CHRO Chromocell Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	2.7928 of 5 stars	3.3	2.0	0.0	0.0	3.0	1.7	1.3
WINT Windtree Therapeutics	2.8772 of 5 stars	3.0	4.0	0.0	0.0	3.8	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	3.00	Buy	$30.00	273.37% Upside
CHRO Chromocell Therapeutics	0.00	N/A	N/A	N/A
CLRB Cellectar Biosciences	2.50	Moderate Buy	$375.00	8,384.16% Upside
WINT Windtree Therapeutics	2.00	Hold	$350.00	67,650.68% Upside

Current Analyst Ratings Breakdown

Latest WINT, CHRO, ADXN, and CLRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	CLRB Cellectar Biosciences	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$460K	18.52	N/A	N/A	$10.37 per share	0.77
CHRO Chromocell Therapeutics	N/A	N/A	N/A	N/A	($1.65) per share	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$8.98 per share	N/A
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	$38.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	$8.02M	-$0.34	N/A	∞	N/A	3,584.49%	-54.27%	-49.15%	9/1/2025 (Estimated)
CHRO Chromocell Therapeutics	-$7.38M	-$1.24	N/A	∞	N/A	N/A	N/A	-453.90%	N/A
CLRB Cellectar Biosciences	-$44.58M	-$21.92	N/A	N/A	N/A	N/A	-619.70%	-158.04%	N/A
WINT Windtree Therapeutics	-$1.79M	-$823.47	N/A	N/A	N/A	N/A	-227.93%	-56.46%	8/18/2025 (Estimated)

Latest WINT, CHRO, ADXN, and CLRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	WINT Windtree Therapeutics	-$39.00	-$4.63	+$34.37	-$4.63	$2.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
CHRO Chromocell Therapeutics	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	3.02	3.02
CHRO Chromocell Therapeutics	N/A	0.60	0.60
CLRB Cellectar Biosciences	N/A	2.47	2.47
WINT Windtree Therapeutics	N/A	0.25	0.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
CHRO Chromocell Therapeutics	77.96%
CLRB Cellectar Biosciences	16.41%
WINT Windtree Therapeutics	29.33%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
CHRO Chromocell Therapeutics	16.40%
CLRB Cellectar Biosciences	5.04%
WINT Windtree Therapeutics	0.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
CHRO Chromocell Therapeutics	4	6.49 million	5.04 million	N/A
CLRB Cellectar Biosciences	10	1.81 million	1.72 million	Optionable
WINT Windtree Therapeutics	30	3.66 million	3.65 million	Not Optionable

WINT, CHRO, ADXN, and CLRB Headlines

Recent News About These Companies

Windtree Therapeutics Delays Q2 2025 Report Filing

August 14 at 6:23 PM | tipranks.com

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

August 11, 2025 | globenewswire.com

Windtree Therapeutics Terminates SEISMiC-C Clinical Study

August 11, 2025 | theglobeandmail.com

Windtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study Results

August 7, 2025 | msn.com

Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

August 5, 2025 | taiwannews.com.twT

Windtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy Rollout

July 30, 2025 | msn.com

Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption

July 29, 2025 | globenewswire.com

Windtree Therapeutics Bets $520M on Binance Coin in Unprecedented Crypto Pivot

July 26, 2025 | thecurrencyanalytics.comT

Windtree Therapeutics Commits Up to $700 Million to Build BNB Treasury Following All-Time High

July 26, 2025 | techstory.inT

Windtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency Holdings

July 26, 2025 | msn.com

Windtree Therapeutics Targets $520 Million in Funding to Secure BNB Reserve

July 25, 2025 | beincrypto.comB

Nasdaq-listed Windtree Therapeutics Commits $520M to BNB in Bold Treasury Pivot

July 25, 2025 | blockonomi.com

Windtree Therapeutics Taps $520M to Build BNB Reserves — Is Pharma Going Crypto?

July 25, 2025 | crypto-news-flash.comC

Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy

July 24, 2025 | globenewswire.com

Windtree Shares Soar More Than 100% on BNB Treasury Plans

July 19, 2025 | msn.com

Nasdaq Biotech Firm Windtree to Raise $200M for First-Ever BNB Crypto Treasury0

July 18, 2025 | thecurrencyanalytics.comT

Biotech Company Windtree to Raise Up to $200M for BNB Treasury

July 17, 2025 | coindesk.com

BNB gains 3% following Windtree's plan to launch BNB treasury, H1 report

July 16, 2025 | fxstreet.com

Windtree Becomes First NASDAQ Firm to Add BNB to Its Balance Sheet

July 16, 2025 | blockonomi.com

Windtree to raise $200M to launch a BNB treasury strategy

July 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

WINT, CHRO, ADXN, and CLRB Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$8.00 +0.46 (+6.11%)

As of 08/14/2025 04:00 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Chromocell Therapeutics NYSE:CHRO

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Cellectar Biosciences NASDAQ:CLRB

$4.42 0.00 (0.00%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$4.30 -0.12 (-2.62%)

As of 04:02 AM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Windtree Therapeutics NASDAQ:WINT

$0.52 -0.02 (-3.58%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.51 0.00 (-0.89%)

As of 04:02 AM Eastern

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time